Quick answer: What research shows
Tirzepatide is a once-weekly dual agonist of GIP and GLP-1 receptors. In adults with obesity but without diabetes (SURMOUNT-1), average weight loss ranged roughly 15–21% at 72 weeks depending on dose, alongside improvements in waist circumference, blood pressure and lipids. In people with type 2 diabetes (SURMOUNT-2), average weight loss was lower but still clinically meaningful (around 12–15%).
- Medication is part of a comprehensive plan: nutrition, activity, sleep and ongoing support remain essential.
- Gastrointestinal side effects are the most common and are usually dose-related.
- Not suitable for everyone; certain conditions and medicines require caution or avoidance.
How tirzepatide works for obesity
Tirzepatide targets two metabolic pathways: GLP-1 and GIP receptors. Together, these signals:
- reduce appetite and increase satiety
- slow gastric emptying (you feel fuller for longer)
- improve insulin secretion and reduce glucagon (metabolic effects)
The dual mechanism is thought to enhance weight loss beyond GLP-1–only therapies in some people. Individual responses vary.
Evidence at a glance (SURMOUNT trials)
- SURMOUNT‑1 (obesity, no diabetes): ≈15–21% mean weight loss at 72 weeks (dose-dependent) with lifestyle support.
- SURMOUNT‑3 (obesity, no diabetes): After intensive lifestyle run-in, adding tirzepatide led to additional double‑digit percent weight loss vs placebo.
- SURMOUNT‑4 (maintenance): Continued tirzepatide supported maintenance and further weight loss vs switch to placebo.
- SURMOUNT‑2 (obesity with type 2 diabetes): ≈12–15% mean weight loss at 72 weeks; also improved glycaemia and cardiometabolic markers.
Trials consistently show improvements in waist circumference, blood pressure, triglycerides, and other markers alongside weight loss.
Who may be eligible
Clinical programs often consider tirzepatide for adults who meet one of the following:
- BMI ≥ 30 kg/m², or
- BMI ≥ 27 kg/m² with at least one weight‑related condition (e.g., hypertension, dyslipidaemia, sleep apnoea, insulin resistance or type 2 diabetes).
Situations where tirzepatide may not be appropriate include:
- personal/family history of medullary thyroid carcinoma (MTC) or MEN 2
- history of pancreatitis or severe gastrointestinal disease
- pregnancy, planning pregnancy or breastfeeding
- significant gallbladder disease
- known hypersensitivity to tirzepatide
Only a qualified health professional can assess your circumstances and medications to decide if treatment is suitable.
Dosing and titration overview
Tirzepatide is injected subcutaneously once weekly. Programs usually start low and increase gradually to improve tolerability:
- Typical start: 2.5 mg weekly for 4 weeks
- Then step up every 4 weeks (e.g., 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) as tolerated
The right maintenance dose varies. If side effects occur during a step-up, clinicians may pause or down‑titrate. Never change your dose without medical direction.
Common side effects and important safety notes
Most common (often temporary and dose‑related):
- nausea, vomiting, diarrhoea or constipation
- abdominal discomfort, decreased appetite, reflux
- headache, fatigue, dizziness
Less common but important to discuss and monitor:
- gallbladder issues (e.g., gallstones)
- pancreatitis (seek urgent care for severe abdominal pain)
- hypoglycaemia risk if combined with insulin or sulfonylureas
- potential risk of thyroid C‑cell tumours seen in rodents (human relevance uncertain); contraindicated with personal/family history of MTC or MEN 2
- kidney injury usually secondary to dehydration from GI symptoms
Medicine interactions and special cautions:
- Delayed gastric emptying may affect absorption of some oral drugs.
- Oral contraceptives: discuss backup or alternative methods during initiation and dose increases.
- Alcohol and dehydration can worsen GI effects.
Access in Australia (Mounjaro/Zepbound)
- Indications: Tirzepatide is approved in Australia for type 2 diabetes as Mounjaro. The obesity indication (Zepbound) has been approved; local availability may be staged and subject to supply.
- PBS status: Obesity treatment is generally not PBS‑subsidised; expect private pricing if used for weight management.
- Access pathway: Medical assessment, prescription, pharmacy supply; telehealth is commonly used for eligibility screening and follow‑up.
- Supply: Periodic shortages or quantity limits may occur due to demand.
How prescriptions work · Typical private costs · Avoid red flags when buying
Local clinic pages: Sydney, Melbourne, Brisbane, Perth, Adelaide, Canberra, Gold Coast, Newcastle, Wollongong, Sunshine Coast, Geelong, Hobart, Darwin, Townsville
Results timeline and expectations
- First month: appetite reduction and smaller portions are common; weight change varies.
- By ~12 weeks: many programs reassess progress; dose may be adjusted for effect vs tolerability.
- 6–12 months: most of the total weight loss typically occurs; maintenance strategies become critical.
- Plateaus are normal: nutrition, activity and sleep quality remain key drivers of long‑term success.
How does it compare to semaglutide?
Head‑to‑head and indirect comparisons suggest tirzepatide may deliver greater average weight loss for some people, likely due to its dual GIP/GLP‑1 mechanism. Tolerability and individual response differ. Availability, pricing and supply also influence choice.
Compare semaglutide vs tirzepatide · GLP‑1 Australia guide · Weight loss injections in Australia
What to discuss with your doctor
- Your medical history, medications and risk factors (e.g., pancreatitis, gallbladder disease, thyroid history)
- Previous weight‑management attempts and what worked or did not
- Side‑effect prevention strategies (slow titration, nausea management, hydration)
- Nutrition, activity, sleep and behavioural support to maintain results
- Monitoring plan: weight, waist, blood pressure, lipids, glucose markers and side effects
Frequently asked questions
Is tirzepatide effective for obesity without diabetes?
Yes. In SURMOUNT‑1, adults with obesity but without diabetes lost around 15–21% of their body weight at 72 weeks depending on dose, alongside cardiometabolic improvements.
How quickly do people notice changes?
Appetite changes can appear within weeks. Substantial weight changes are usually assessed over months. Programs often review progress by 12 weeks and again at 6–12 months.
What if I can’t tolerate a higher dose?
Clinicians can pause, down‑titrate or extend each step. Don’t adjust on your own—speak with your prescriber.
Can I use tirzepatide with other weight loss medicines?
Combinations depend on your health status and clinician advice. Some combinations are inappropriate or add risk. Always seek medical guidance.
Does it affect the pill (oral contraceptives)?
Tirzepatide can delay gastric emptying and may reduce absorption of some oral medicines. Discuss backup contraception during initiation and after dose increases.
Is it available for obesity in Australia?
The obesity indication (Zepbound) has TGA approval. Availability and supply can vary by time and location, and obesity treatment is generally not PBS‑subsidised.
What does it cost?
Costs vary by dose and pharmacy. See our overview and speak with a provider for current local pricing.
How is tirzepatide different from semaglutide (Wegovy/Ozempic)?
Tirzepatide activates both GIP and GLP‑1 receptors; semaglutide activates GLP‑1 only. Average weight loss can differ between drugs and doses. Your clinician can help compare options.
Where can I learn more?
See our focused pages: Tirzepatide for weight loss, Type 2 diabetes use, Side effects, Results timeline, Reviews guide.
Final takeaway
Tirzepatide for obesity can produce significant, clinically meaningful weight loss and health improvements when combined with lifestyle support. It is not suitable for everyone and requires medical supervision, careful titration and long‑term maintenance strategies.
Ask about tirzepatide for obesity
Have questions about eligibility, dosing, access or side effects? Send a message and a team member can guide you to appropriate medical providers.
Prefer to talk later? Contact page